Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: A cost-utility analysis

Woods, B; Hawkins, N; Dunlop, W; O'Toole, A; Bramham-Jones, S; (2012) Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: A cost-utility analysis. Value in health, 15 (5). pp. 759-70. ISSN 1098-3015 DOI: https://doi.org/10.1016/j.jval.2012.03.1389

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.jval.2012.03.1389

Abstract

Item Type Article
Keywords Age Factors, Aged, Alkylating, Alkylating: economics, Alkylating: therapeutic use, Antineoplastic Agents, B-Cell, B-Cell: drug thera, B-Cell: economics, Chlorambucil, Chlorambucil: economics, Chlorambucil: therapeutic use, Chronic, Cost-Benefit Analysis, Disease-Free Survival, England, Humans, Leukemia, Lymphocytic, Markov Chains, Middle Aged, National Health Programs, Nitrogen Mustard Compounds, Nitrogen Mustard Compounds: economics, Nitrogen Mustard Compounds: therapeutic use, Quality of Life, Quality-Adjusted Life Years, Treatment Outcome, United Kingdom, Wales, anemia, antibiotic agent, antineoplastic agent, article, bendamustine, blood transfusion, cancer growth, cancer survival, chlorambucil, chronic lymphatic leukemia, codeine, cost effectiveness analysis, cost utility analysis, cyclophosphamide, cytopenia, diarrhea, domperidone, erythropoietin, fever, fludarabine, health care cost, human, loperamide, maxolon, meta analysis, metoclopramide, multiple cycle treatment, nausea, overall survival, piperacillin plus tazobactam, pneumonia, priority journal, probability, progression free survival, quality adjusted life year, quality of life, recombinant granulocyte colony stimulating factor, sensitivity analysis, systematic review, tazocin, treatment outcome, treatment response, vomiting, Age Factors, Aged, Antineoplastic Agents, Alkylating, economics, therapeutic use, Bendamustine Hydrochloride, Chlorambucil, economics, therapeutic use, Cost-Benefit Analysis, Disease-Free Survival, England, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, economics, Markov Chains, Middle Aged, National Health Programs, Nitrogen Mustard Compounds, economics, therapeutic use, Quality of Life, Quality-Adjusted Life Years, Treatment Outcome, Wales
Faculty and Department Faculty of Public Health and Policy > Dept of Health Services Research and Policy
PubMed ID 22867787
ISI 307311100021

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar